Effect of intravariceal sclerotherapy combined with esophageal mucosal sclerotherapy using small-volume sclerosant for cirrhotic patients with high variceal pressure

Table 1 Demographic profile of the study population

	EVL group(n = 20)	Combined group(n = 18)	P value
Sex			0.208
M	14	9
F	6	9
Age (yr)	53.55 ± 13.72	52.94 ± 14.96	0.897
Child-Pugh grade			0.875
A	9	8
B	11	10
Etiology			1.000
HBV-related	10	10
Alcohol	2	1
PBC	2	2
Cryptogenic	4	4
VP (mmHg)	21.60 ± 3.25	22.04 ± 3.87	0.274
Varix grade			0.612
F2	10	9
F3	10	11

VP: Variceal pressure; PBC: Primary biliary cirrhosis; EVL: Endoscopic variceal ligation; HBV: Hepatitis B virus.

Table 2 Follow-up characteristics

	Combined group(n = 18)	EVL group(n = 20)	P value
Rebleeding	1	3	0.606
Eradication	18	18	0.488
Time to eradication (d)	48.5 ± 21.7	56.1 ± 30.5	0.749
Recurrence	1	7	0.045a
Mortality	0	0	1.000

^aP < 0.05, combined group vs EVL group, Student’s t test. EVL: Endoscopic variceal ligation.